Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967989 | 0.82 | MAPT (0.47) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL2159856 | 0.79 | MEN1 (0.48) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL12394775 | 0.79 | MEN1 (0.56) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL3119242 | 0.77 | MEN1 (0.54) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL1964930 | 0.76 | MEN1 (0.49) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL3700015 | 0.74 | MEN1 (0.49) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL19304856 | 0.74 | KMT2A (0.74) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL1964353 | 0.74 | MEN1 (0.54) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL1967149 | 0.73 | MEN1 (0.46) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL2161013 | 0.72 | MAPK1 (0.52) | MEN1KMT2ATDP1POLBHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172096-A1 | Triazole Compounds, The Use Thereof and Preparations Containing These Compounds | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2334654-A1 | TRIAZOLE COMPOUNDS, THE USE THEREOF AND PREPARATIONS CONTAINING THESE COMPOUNDS | BASF SE (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010029002-A1 | TRIAZOLE COMPOUNDS, THE USE THEREOF AND PREPARATIONS CONTAINING THESE COMPOUNDS | BASF SE (DE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172096-A1 | Triazole Compounds, The Use Thereof and Preparations Containing These Compounds | CYP11B2, CYP3A43, CYP3A5 | MEN1 625/4885KMT2A 3160/4885TDP1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.